Sarepta Therapeutics
Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
SRPT Key Statistics
Stock Snapshot
As of today, Sarepta Therapeutics(SRPT) shares are valued at $19.97. The company's market cap stands at 2.09B, with a P/E ratio of -2.37.
During the trading session on 2026-03-29, Sarepta Therapeutics(SRPT) shares reached a daily high of $22.03 and a low of $19.72. At a current price of $19.97, the stock is +1.3% higher than the low and still -9.4% under the high.
Trading volume for Sarepta Therapeutics(SRPT) stock has reached 4.61M, versus its average volume of 4.52M.
The stock's 52-week range extends from a low of $10.42 to a high of $72.05.
The stock's 52-week range extends from a low of $10.42 to a high of $72.05.
SRPT News
Earlier this week, Sarepta Therapeutics reported the first human data from its SRP-1001 and SRP-1003 siRNA programs in FSHD1 and DM1, showing dose-dependent mus...
Shares of Sarepta Therapeutics SRPT rose 35% on Wednesday after the company announced early clinical data on two experimental siRNA therapies, which were acquir...
Deutsche Bank raised the firm’s price target on Sarepta (SRPT) to $14 from $12 and keeps a Sell rating on the shares. The company yesterday exported positive pr...
Analyst ratings
50%
of 26 ratingsMore SRPT News
H.C. Wainwright analyst Mitchell Kapoor has reiterated their bearish stance on SRPT stock, giving a Sell rating yesterday. Mitchell Kapoor has given his Sell r...
Citi analyst Yigal Nochomovitz has maintained their bearish stance on SRPT stock, giving a Sell rating on March 19. Yigal Nochomovitz has given his Sell rating...
Citi analyst Yigal Nochomovitz raised the firm’s price target on Sarepta (SRPT) to $13 from $9 and keeps a Sell rating on the shares. The firm says yesterday’s...
U.S. stocks closed higher on Wednesday, with the Dow Jones Industrial Average up 0.66% at 46,429.49, the S&P 500 gaining 0.5% to 6,591.90 and the Nasdaq advanci...
Morgan Stanley raised the firm’s price target on Sarepta (SRPT) to $25 from $20 and keeps an Equal Weight rating on the shares. Early Phase 1/2 data in faciosca...
After Sarepta (SRPT) Therapeutics shared the first clinical results from two of its siRNA programs for neuromuscular diseases, Leerink analyst Joseph Schwartz s...
Oppenheimer analyst Kostas Biliouris says Sarepta’s (SRPT) myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy data “appear promising.” However...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.